Article ID Journal Published Year Pages File Type
5670724 World Journal of Otorhinolaryngology - Head and Neck Surgery 2016 4 Pages PDF
Abstract

ObjectiveTo review the indications and clinical evidence supporting hypoglossal nerve stimulation (HNS) therapy for the treatment of moderate-to-severe obstructive sleep apnea (OSA).MethodsPeer reviewed literature on hypoglossal nerve stimulation therapy for obstructive sleep apnea from 2001 to 2016.ResultsThe only currently FDA-approved HNS device for the treatment of moderate-to-severe OSA is produced by Inspire Medical Systems, which recently published its 36-month outcomes data from its Stimulation Therapy for Apnea Reduction (STAR) trial. HNS therapy is currently indicated for moderate-to-severe OSA patients who are CPAP-intolerant, have a body mass index <32, apnea-hypopnea index <50, and without a concentric pattern of upper airway collapse on sleep endoscopy.ConclusionsData from the STAR trial suggests that a subset of OSA patients can achieve a significant therapeutic response from hypoglossal nerve stimulation. However, these results may be limited in their generalizability to the broader OSA population.

Related Topics
Health Sciences Medicine and Dentistry Immunology, Allergology and Rheumatology
Authors
, ,